ArticleJournal of food and drug analysis2025
Jiao San Xian granule containing prebiotic alleviate functional dyspepsia by regulating intestinal flora and the secretion of inflammatory response.
Article in Journal of food and drug analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enterococcus in herbal fermentation: a genus-specific perspective on enzymatic capability, biotransformation outcomes and safety.Archives of microbiology · 2026Review
- Mechanisms of Xinwei Tang in stress-induced gastric dysmotility: evidence from rat and In Vitro models.In vitro cellular & developmental biology. Animal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Jiao Sanxian (JSX) consists of three traditional Chinese medicine including charred hawthorn, malt and Liu Shen Qu, they are also from Chinese medicine homologous food. It is commonly used to relieve functional dyspepsia (FD). The present study aims to explore the mechanism of JSX (granule), with the addition of prebiotics for the treatment of FD using mice model. The network pharmacology and molecular docking were used to forecast therapeutic targets for JSX. Based on the protein-protein interaction (PPI) results, thirteen targets exhibited strong interactions with each other. The results of network pharmacology and molecular docking revealed therapeutic activity of JSX in FD regulated by its anti-inflammatory effect, improvement in gastrointestinal function and physiological activity in components-targets-pathways-disease. The pharmacological effects of JSX were further verified by rRNA gene sequencing, enzyme-linked immunosorbent assay (ELISA) and animal study. The in vivo results showed JSX, in combination with prebiotics, could mitigate FD symptoms. ELISA study showed that glyceraldehyde-3-phosphate dehydrogenase (GAPDH), AKT1 and tumor necrosis factor (TNF)-α played the roles in reducing the inflammatory response by downregulating inflammation content. The above results were coincided with the network pharmacology prediction. By 16S rRNA, the results showed JSX may alleviate the FD symptom by increasing the diversity of the intestinal flora, adjusting the dominant prebiotic. In conclusion, JSX can alleviate functional dyspepsia in mice. The mechanisms were related to regulating the secretion of inflammatory response, significantly improving the benefits of intestinal flora and ameliorating multi-metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.